NASDAQ · MPLT

MapLight Therapeutics, Inc.

Healthcare · Biotechnology

$12.93▼ 0.53% ($0.07)today

As of 2:16 PM ET

52-week

$9.10$40.43

Market cap

$548.74M

P/E

Valuation

Recommended · Earnings yield

Price used

$12.93

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 4.96%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 14, 2026, 6:16 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 14, 2026, 6:17 PM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 1 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -29.36%FCF (TTM): -72.69%

What changed

The stock fell 29.36% over the last year. Free cash flow declined 72.69% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Free cash flow fell 72.69% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Monthly returns

Company profile

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders.

CEOChristopher A. Kroeger

SectorHealthcare

IndustryBiotechnology

Employees133

IPO dateOct 24, 2025

https://www.maplightrx.com

Market multiples

Forward P/E—

EV/EBITDA-4.56

Enterprise value$732.58M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-111.55%▼55.4ppvs FY2025

Analyst consensus

RatingBuy

Target price$29.20▲125.82%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Sep 18, 2026

Q4 FY26 · EPS est -$1.35 · Revenue est —

View